Actinium Pharmaceuticals, a
biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers, is presenting a
corporate today at 1:30 pm ET at the 16th Annual BIO CEO & Investor
Conference.
Today’s presentation will be
held at The Waldorf-Astoria Hotel: Conrad Room, New York, NY. There will also
be a webcast available at:
http://www.veracast.com/webcasts/bio/ceoinvestor2014/68234189.cfm/.
A replay of the webcast will
also be archived on Actinium’s website for 90 days following the presentation.
According to the American
Cancer Society, half of all men and one third of all women will develop at
least one form of cancer during their lifetime. There are more than 1.5 million
new cancer cases per year in the U.S. and nearly 12.7 million worldwide,
excluding non-melanoma skin cancers. Worldwide sales of biopharmaceutical
products for treating cancer are approximately $50 billion per year, with U.S.
sales being approximately half of that. Biopharmaceutical cancer treatments
include a variety of drugs, but two categories predominate: cytotoxic
chemotherapy and targeted therapies. Other approaches (e.g., hormonal therapy,
phototherapy, cryotherapy, etc.) are used less frequently.
Actinium Pharmaceuticals is
a New York-based biopharmaceutical company developing innovative targeted
payload immunotherapeutics for the treatment of advanced cancers. The company’s
targeted radiotherapy is based on its proprietary delivery platform for the
therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and
certain beta emitting radiopharmaceuticals in conjunction with monoclonal
antibodies.
For more information on
Actinium Pharmaceuticals, its biopharmaceutical innovations, and their
progress, please visit: www.actiniumpharmaceuticals.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
